Ascletis Advances ASC37 Triple Agonist to Clinical Stage
January 21, 2026 | 15:21
The biopharmaceutical company selected its once-monthly injectable candidate targeting three metabolic receptors for clinical trials, progressing its pipeline for diabetes and obesity treatment.
Mobile Version